Testing FIB-4 for liver scarring in obesity
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at how a simple blood test (FIB-4) can help check for liver scarring in people with obesity. It aims to find better ways to detect early liver problems, so you may benefit from closer monitoring or early treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a BMI between 30 and 40 (Class I or II obesity).
- You are between 18 and 65 years old.
- You do not have other known liver diseases (like hepatitis, cirrhosis, or liver cancer).
- You are not currently taking certain weight-loss or diabetes medications (Semaglutide or Tirzepatide).
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This study uses a special ultrasound device called FibroScan to check for fatty liver disease (MASLD) in people with obesity who are planning to have weight-loss surgery. The results will be compared to a liver biopsy to see how well the device works.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study tests a simple blood test (FIB-4) to check for liver scarring in people with type 2 diabetes. It may help find liver problems early so you can get the right care.
Hear when a new MASLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.